CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 81 enrolled
Drug / intervention
DermDxdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06463860
NCT06463860N/ACompleted

Retrospective, Multi-Center Study to Evaluate the Performance of DermDx as an Adjunctive Tool for Primary Care Physicians in the Detection of Skin Cancers

MetaOptima Technology Inc.·observational·Posted Jun 18, 2024·Updated Dec 19, 2024

In Brief

An observational study evaluating DermDx for Skin Cancer. Completed, enrolled 81 participants across 1 site.

Detailed Summary

The proposed study is a pivotal, multi-center retrospective reader study designed to determine whether the use of DermDx as a concurrent reading aid improves the performance of primary care physicians (PCPs) in diagnosing skin cancers.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedJun 18, 2024
Enrollment StartJun 12, 2024
Primary CompletionNov 27, 2024
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.0 years ago

Interventions

DermDxdevice

DermDx is a computer-aided diagnosis (CADx) software product that uses an AI-based algorithm to evaluate non-invasively captured images of skin lesions obtained from any commercially available dermoscopes. DermDx uses state-of-the-art deep neural network models that have been trained on a large database of dermoscopy images. DermDx analyzes the image of a new skin lesion and provides an output.